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ABSTRACT
Introduction. Colorectal cancer is one of the most frequent cancers in the world and
liver metastases are seen in up to 19% of patients with colorectal cancers. Detection
of liver metastases is not only vital for sufficient treatment and survival, but also for a
better estimation of prognosis. The aim of this study was to evaluate the feasibility of
diffusion weighted MRI of the liver as part of a combined MR evaluation of patients
with rectal cancers and compare it with the standard preoperative evaluation of the
liver with CT.
Methods. Consecutive patients diagnosed with rectal cancers were asked to partici-
pate in the study. Preoperative CT and diffusion weighted MR (DWMR) were com-
pared to contrast enhanced laparoscopic ultrasound (CELUS).
Results. A total of 35 patients were included, 15 patients in Group-1 having the
standard CT evaluation of the liver and 20 patients in Group-2 having the standard
CT evaluation of the liver and DWMR of the liver. Compared with CELUS, the
per-patient sensitivity/specificity was 50/100% for CT, and for DWMR: 100/94%
and 100/100% for Reader 1 and 2, respectively. The per-lesion sensitivity of CT and
DWMR were 17% and 89%, respectively compared with CELUS. Furthermore, one
patient had non-resectable metastases after DWMR despite being diagnosed with
resectable metastases after CT. Another patient was diagnosed with multiple liver
metastases during CELUS, despite a negative CT-scan.
Discussion. DWMR is feasible for preoperative evaluation of liver metastases. The
current standard preoperative evaluation with CT-scan results in disadvantages like
missed metastases and futile operations. We recommend that patients with rectal can-
cer, who are scheduled for MR of the rectum, should have a DWMR of the liver per-
formed at the same time.
Subjects Clinical Trials, Gastroenterology and Hepatology, Radiology and Medical Imaging,
Surgery and Surgical Specialties
Keywords Contrast enhanced ultrasound, Magnetic resonance imaging, Metastasis rectal cancer,
Diffusion weighted magnetic resonance, Computed tomography
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INTRODUCTION
Colorectal cancer is one of the most frequent cancers in the world with approximately
1.4 million new cases and 700.000 estimated deaths in the 2012 worldwide (International
Agency for Research on Cancer, 2012). Liver metastases are seen in up to 19% of patients
with colorectal cancers and other 14–20% metachronous liver metastases are seen during
the subsequent five years for patients without initial synchronous metastases (Ghiringhelli
et al., 2014; Landreau et al., 2015;Manfredi et al., 2006; Leporrier et al., 2006).
Detection of liver metastases is not only vital for sufficient treatment and survival,
but also for a better estimation of prognosis. Currently, the best treatment and chance of
survival for patients with liver metastases, both synchronous and metachronous, is either
surgery or radiofrequency ablation (RFA). The five year overall survival with synchronous
liver metastases without treatment at this time is approximately 3.3% (Manfredi et al.,
2006), compared with a 5-year overall survival of 46% for patients with resected syn-
chronous liver metastases (Harmon et al., 1999). Although the rate of synchronous liver
metastases have been stable over the last decades, a decrease in metachronous metastases
has been seen primarily due to better neo-adjuvant treatment (Leporrier et al., 2006). This
underlines the importance of preoperative evaluation in patients with colorectal cancer
in order to offer the best treatment: resection, neo-adjuvant chemotherapy or palliative
treatment.
Numerous non-invasive preoperative methods for detection of liver metastases have
been proposed and described. Among others computed tomography (CT), magnetic
resonance imaging (MRI), Fludeoxyglucose positron emission tomography (FDG-
PET), and contrast enhanced ultrasonography. Furthermore, several factors should be
considered when choosing a modality for preoperative liver assessment: reproducibility,
time consumption, cost, operator dependency, and availability for re-assessment. In
Denmark, standard preoperative evaluation in patients with rectal cancer is a CT tho-
rax/abdomen, combined with MRI of the rectum and colonic evaluation by colonoscopy
(Sundhedsstyrelsen). In an earlier published study, we reported colonic evaluation in
patients with rectal cancer using either magnetic resonance (MR) colonography or
standard care (Achiam et al., In press). In this patient population the obligatory MRI of
the rectum was combined with MR colonography and diffusion weighted MR (DWMR)
of the liver on the same day as CT thorax/abdomen.
The aim of this study was to evaluate the feasibility of DWMR imaging of the liver as
part of a combined MRI evaluation of patients with rectal cancers and compare it to the
standard preoperative evaluation of the liver with CT.
MATERIALS AND METHODS
Study population
From October 2010 to February 2013, consecutive patients diagnosed with rectal cancers
were asked to participate in the study. The current study is a secondary analysis with
different endpoints than the primary study, design and eligibility criteria are described
earlier (Achiam et al., In press). The patients were randomized to either Group-1:
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standard preoperative diagnostic liver evaluation (CT of thorax/abdomen) or Group-2:
preoperative MR diagnostic work-up (CT of thorax/abdomen and DWMR of the liver).
CT and DWMR were carried out on the same day. Randomization was performed using
the website www.random.org. A computer-generated randomization schedule using fixed
size blocks assigned patients to either group-1 or group-2 using a 1:1 ratio.
The primary endpoint of this study was the feasibility of DWMR imaging of the liver
as part of a combined MRI evaluation of patients with rectal cancers. The secondary
endpoints were a per-patient and per-lesion analysis for CT and DWMR imaging of liver
metastases and a comparison of the two modalities.
Evaluation
Preoperative CT and DWMR were compared to contrast enhanced laparoscopic ultra-
sound (CELUS), open liver surgery with ultrasound or consensus reached at the multi-
disciplinary team conference if surgery was not performed within six months. Contrast
enhanced ultrasound was chosen as the control measure to compare for both of CT scan
and MRI, since it could be performed as an intraoperative procedure in both groups.
Furthermore, studies have found additional metastases and high sensitivities in evaluating
especially smaller liver metastases with intraoperative contrast enhanced ultrasound
(D’Onofrio et al., 2009;Wildi et al., 2008). The multidisciplinary team board consisted
of highly specialized consultants from the specialties: colorectal surgery, hepatobiliary
surgery, radiology, oncology and pathology. Furthermore, the patients were monitored
at a postoperative follow-up visit. The postoperative follow-up consisted of a visit at
an out-patient unit and further diagnostics (CT, contrast enhanced ultrasonography or
FDG-PET/CT) if the patient had symptoms of recurrence or a carcinoembryonic antigen
(CEA) value>4 mg/L. To be considered true positive finding, a lesion had to be within
the same or adjacent liver segment and had to have the same size±25% as a lesion found
on CELUS or supplemental scans. All metastases were defined from a histopatological
confirmation when possible or based on the morphological characteristics according to
diagnostic modality if no surgical specimen was available. Liver metastases were defined as
synchronous metastases, if they were either confirmed or found on CELUS, supplemental
scans or subsequent follow-up scans within six months. Liver metastases found after six
months on follow-up were defined as metachronous metastases.
CT technique
The CT examination of thorax, abdomen and pelvis were performed on Philips Brilliance
Premium 64 slice, Philips Brilliance 64 slice, or Philips MX 8000 IDT (16 slice) machines
(Brilliance; Philips Healthcare, DA Best, the Netherlands). Intravenous contrast, Iomeprol
350 mgI/ml, according to bodyweight, was injected prior to the examination. The exam-
ination was performed at 60–70 s timed delay to obtain the portovenous contrast phase.
The department’s usual technical parameters were used for the examination; 120 kV and
300 mAs, with 64×0.625 mm or 16×1.5 mm collimation, reconstructed to 3 mm in axial,
coronal and sagittal plane. Hypodense lesions in the parenchyma which showed no sign of
being a cyst or haemangioma in the portal-venous phase of a contrast enhanced CT were
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considered liver metastases. Finding of metastatic lesions were documented and recorded
by the size and segmental location in the liver.
MRI technique
All MRI examinations were performed on a 1.5T system (Achieva, Philips Healthcare,
Best, the Netherlands) in three stations: pelvic, liver and bowels. For liver, a 16 channel
phased array coil was used and an axial T2-weighted respiratory triggered Single Shot
Turbo Spin Echo sequence (time to echo (TE) 80 ms, field of view (FOV) 430×330 mm,
matrix 300× 206, 7 mm slice thickness acquisitions time (TA) 1:15 min), a breath hold
axial dual echo gradient echo (GE) sequence, time to repeat (TR)/TE/TE: 142/2.3/4.6 ms,
FOV 400× 327 mm, matrix 308× 193, 5 mm slice thickness, TA 38 s; a respiratory
triggered axial DWI (TR/TE 1301/56 ms FOV, 400×322 mm, matrix 144×94, b-values
of 0, 10, 150, 300, 450, 8 mm slice thickness, TA 3 min. Apparent Diffusion Coefficient
map was calculated on basis of b 0, 150, 300 and 450. Furthermore, an axial breath hold
T1w fat saturated GE sequence was obtained before and after intravenous injection of
0.1 mmol/kg body weight gadoterate meglumin TR/TE 4/1.95 ms, FOV 375× 295 mm,
matrix 188× 147, 4 mm slice thickness TA 20.3 s, followed by a coronal breath hold
T1w GE fat saturated sequence TR/TE 4/1.95 ms, FOV 375×375 mm, matrix 192×192,
4 mm slice thickness, TA 22 s. Hypointense lesions on T1w, variable hyperintense on T2w,
hyperintense on DWI and hypointense on ADC map were considered liver metastases.
Finding of metastatic lesions were documented and recorded by the size and segmental
location in the liver.
Contrast enhanced laparoscopic ultrasound
Laparoscopic ultrasound was performed via one of the 10-mm laparoscopic ports using a
dedicated ultrasound probe with a flexible tip that allows good contact between the liver
surface and the probe tip with the curved array transducer (Transducer type 8666; BK
Medical Ultrasound System, Herlev, Denmark). The entire liver was thorough examined
for focal lesions with conventional B-mode and with contrast mode. Approximately
2.4 ml of ultrasound contrast agent (Sonovue, Bracco, Milan, Italy) was given intra-
venously and laparoscopic ultrasound (with the system in Low-MI contrast-mode) was
performed after 30 s (in the venous phase). Solid liver lesions showing hypovascularity
(wash out) were considered liver metastases. Finding of metastatic lesions were docu-
mented and recorded by the size and segmental location in the liver.
Image analysis
CT-images were, as part of the standard operating procedure for patients with rectal
cancer, evaluated by radiologists assigned to the abdominal team. The radiologist, who
was on duty the day the CT-scan was performed, evaluated the standard CT of the liver.
MR images of the liver were anonymized and randomized by a computer before
being blindly evaluated by two evaluators. One reader was a board-certified abdominal
radiologist with more than 15 years of experience in MR abdominal imaging, but with
limited experience interpreting DWMR. The other reader was an experienced research
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radiographer with more than 10 years of experience in abdominal imaging and extensive
experience evaluating and designing DWMR scan sequences.
CELUS were evaluated by three board-certified abdominal radiologists specialized in
ultrasonography examination, each with more than 15 years of experience in abdominal
ultrasonography.
STATISTICAL ANALYSIS
For categorical and continuous data, Fisher’s exact test, Pearson X 2 test and Mann–
Whitney U test were used when appropriate. SPSS version 19 (IBM version 20.0) was
used for the statistical analyses. P-values<0.05 were regarded significant.
ETHICS
The study was approved by the research ethics committee, Capital Region of Denmark
(protocol number: H-1-2009-094) and registered at clinicaltrials.gov (NCT01544452) and
all patients participated after informed consent.
RESULTS
Initially, 75 patients were included in the primary study of which 19 were excluded
(reasons are as follows: Patients excluded due to: 6 not undergoing operation, 3 due to
benign tumor, 3 due to liver metastases, 2 withdrawal of consent, 1 due to MR missing
capacity, 1 due to sigmoid cancer, 1 due to preoperative death, 1 due to CT technical
difficulties, 1 due to MR technical difficulties) (Achiam et al., In press). In total 56 patients
were included in the primary study. One patient, randomized to Group-2, was excluded
in the primary study, since the MR scanner had technical difficulties after the MR
sequence of the rectum. Thus, the MR colonography and DWMR were not performed.
However, since the patient both had a standard CT thorax/abdomen and a CELUS, the
patient was allocated to Group-1 in the current study (Fig. 1).
From the 57 patients, 22 patients were excluded as they did not have surgery and a
CELUS or open ultrasound within six months or a multidisciplinary team consensus.
Thus, Group-1 consisted of 15 patients having the standard preoperative evaluation of
the liver, and Group-2 consisted of 20 (16 male, 4 female) patients having the standard
CT evaluation of the liver and DWMR of the liver. Age, sex, and T- and N-stage were
comparable between the groups and are shown in Table 1.
Group-1
CT per-patient analysis
Compared to CELUS findings, CT of the liver correctly identified one patient with
liver metastasis. Another patient had liver metastases, all of which were not revealed.
No patients had false positive findings (Table 2). The sensitivity, specificity, positive
predictive value (PPV) and negative predictive value (NPV) are shown in Table 3.
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Figure 1 Flowchart of patients included.DWMR, Diffusion weighted magnetic resonance; CELUS,
Contrast enhanced laparoscopic ultrasound.
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Table 1 Patient characteristic in Group-1 and 2.
Group-1 Group-2 P-value
N % N %
Sex 0.266a
Female 6 40.0 4 20.0
Male 9 60.0 16 80.0
Age Median (IQR) 62 (19) 64 (17) 0.657b
Preoperative T-stage 1.000a
2 5 33.3 7 35.0
3 10 66.7 13 65.0
Preoperative N-stage 1.000a
0 8 53.3 11 55.0
1 & 2 7 46.7 9 45.0
Notes.
IQR, Interquartile range.
aFisher’s exact test.
bMann–Whitney U test.
Table 2 Findings on CT and diffusion weightedMR.
Notes.
CELUS, Contrast enhance laparoscopic ultrasound.
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Table 3 Per-patient and per-lesion analysis for CT and diffusion weightedMR.
Per-patient analysis Per-lesion analysis
CT
Group 1
CT
Group 2
CT
Group 1+2
MR
Reader 1
MR
Reader 2
CT
Group 1
CT
Group 2
CT
Group 1+2
MR
Reader 1
MR
Reader 2
Sensitivity 50% 50% 50% 100% 100% 13% 22% 17% 89% 89%
Specificity 100% 100% 100% 94% 100%
PPV 100% 100% 100% 67% 100% 100% 100% 100% 89% 100%
NPV 93% 95% 94% 100% 100%
Notes.
Sensitivity, True positive/true positive+ false negative; Specificity, True negative/true negative+ false positive; Positive predictive value (PPV), True positive/true positive+
false positive; Negative predictive value (NPV), True negative/true negative+ false negative.
Table 4 Characteristics of synchronous liver metastases.
Patient
number
Group Lesion
no
CT
segment/size
DWMRReader 1
Segment/size
DWMRReader 2
Segment/size
IOCEUS/MDT
Segment/size
1 1 1 NF – – Segment 5/6 mm
2 Segment 7/12 mm – – Segment 7/20 mm
2 1 1 NF – – Segment 3/8 mm
2 NF – – Segment 6/6 mm
3 NF – – Segment 6/7 mm
4 NF – – Segment 7/10 mm
5 NF – – Segment 8/5 mm
6 NF – – Segment 8/8 mm
3 2 1 Segment 4/55 mm Segment 4/65 mm Segment 4/70 mm Segment 4/68 mm
2 NF Segment 5/8 mm Segment 5/5 mm Segment 5/6 mm
3 NF Segment 5/7 mm Segment 5/7 mm Segment 5/7 mm
4 Segment 7/13 mm Segment 7/18 mm Segment 7/10 mm Segment 7/13 mm
5 NF Segment 8/11 mm Segment 8/7 mm Segment 8/7 mm
6 NF Segment 8/11 mm Segment 8/12 mm Segment 8/11 mm
7 NF Segment 8/13 mm Segment 8/16 mm Segment 8/19 mm
4 2 1 NF Segment 5/23 mm Segment 5/25 mm Segment 5/17 mm
3 NF NF NF Segment 5/14 mm
Notes.
DWMR, Diffusion weighted magnetic resonance; MDT, Multidisciplinary team; NF, not found.
CT per-lesion analysis
Compared to CELUS findings, one of 8 synchronous liver metastases was correctly
identified and no false positive lesions were recorded on CT (Table 2). The sensitivity and
PPV are shown in Table 3. The lesions are described in Table 4.
Consequence of CT findings
One patient had a true positive metastasis of 12 mm in segment-7, but during CELUS a
6 mmmetastasis in segment-5 was also identified. Surgical strategy was changed, both
metastases were treated with RFA and at the 12 months follow-up no sign of recurrence
was found.
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Another patient was found without metastases on CT of the liver. However, at the
CELUS, several metastases (8 mm segment-3, 6 & 7 mm segment-6, 10 mm segment-7, 8
& 5 mm segment-8) were found. The patient was committed to transarterial chemoem-
bolization FOLFOX-TACE treatment (Martin et al., 2009) and after five months the
patient no longer had identifiable metastases.
Time from scan to operation
The median time from CT-scan to operation was 2 weeks (range 1–20).
Group-2
CT per-patient analysis
Compared to CELUS findings, CT of the liver correctly identified one patient with liver
metastasis. One patient had liver metastases which were not seen on CT. No patients with
false positive findings were found (Table 2). The sensitivity, specificity, PPV and NPV are
shown in Table 3.
CT per-lesion analysis
Compared to CELUS findings, two of nine synchronous liver metastases were correctly
identified and no false positive lesions were recorded on CT (Table 2). The sensitivity,
specificity, PPV and NPV are shown in Table 3. The lesions are described in Table 4.
MR per-patient analysis
Compared to CELUS findings, Reader 1 identified the two patients with liver metastases.
No patients with liver metastases were missed. One patient had a false positive finding
(Table 2). Reader 2 identified the two patients with liver metastases. No patients with liver
metastases were missed and/or had false positive findings. The sensitivity, specificity, PPV
and NPV are shown in Table 3.
MR per-lesion analysis
Compared to CELUS findings, Reader 1 correctly identified eight liver metastases. One
lesion was overlooked (Fig. 2) and one false positive lesion was reported (Table 2). Reader
2 also identified eight out of eight liver metastases. A single lesion was overlooked and no
false positive lesions were reported. The sensitivity and PPV are shown in Table 3.
Consequences of DWMR findings
In one patient with rectal cancer, two liver metastases (55 mm segment-4 and 13 mm
segment-8), were initially found to be resectable (Fig. 3) on CT of the liver. However,
DWMR subsequently found multiple metastases (Table 3 and Fig. 3). On the basis of
the finding on DWMR, the metastases were found to be non-resectable and surgery
was cancelled. Instead, the patient was committed to neoadjuvant treatment using
transarterial chemoembolization with FOLFOX. After four months of treatment, the
patient underwent a liver resection with findings of metastases in segment 4, 5, 6, and 8.
The patient had a rectum extirpation two months later and at the 12 months follow-up,
no sign of recurrence was found.
In another patient with rectal cancer, no liver metastases were found on the initial CT
scan, but retroperitoneal metastases were found. Subsequently, a liver metastasis (23 mm
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Figure 2 Missed liver metastasis on CT and diffusion weightedMR. (A) Initial CT, (B) Diffusion
weighted MR, (C) subsequent CT after 5 months of neoadjuvant therapy. Broken arrow: Metastasis
missed on primary CT and diffusion weighted MR.
Figure 3 Missed liver metastasis segment 7 & 8 on CT and diffusion weightedMR. (A) Initial CT, (B)
Diffusion weighted MR, (C) CT in venous phase. White arrow: Segment 4 metastasis. Black arrow: Two
metastases missed on primary CT.
segment-5) was found on the DWMR (Fig. 4). On the basis of the finding on DWMR and
CT the patient was committed to neoadjuvant treatment and underwent rectum resection
after seven months of treatment. Eight months after surgery the patient was diagnosed
with multiple metastases in the lungs, but no liver metastases. At the last follow-up scan
(26 months postoperatively) no liver metastases were detected.
One patient had a false positive finding according to Reader 1, however no lesion was
found on the subsequent CELUS and no change of strategy was implemented.
Time from scan to operation
The median time from CT and DWMR to surgery was 2.5 weeks (range 1–33).
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Figure 4 Missed metastasis on initial CT and diffusion weightedMR. (A) Initial CT, (B) Diffusion
weighted MR, (C) CT in venous phase after 3 months of neoadjuvant therapy. Black arrow: Metastasis
missed on primary CT.
Table 5 Type of follow-up scan.
Group Follow-up scan Frequency Percentage
CT 7 47
1 PET/CT 2 13
Contrast enhanced ultrasound 6 40
Total 15 100
2 CT 9 45
None due to comorbidity 1 5
PET/CT 2 10
Contrast enhanced ultrasound 8 40
Total 20 100
CT versus DWMR
The sensitivity, specificity, PPV and NPV of the combined CT findings from Groups-1
and -2 are shown in Table 3. Comparing lesions confirmed on CELUS (9), significantly
more true positive lesions diagnosed found on DWMR (8) compared with lesions found
on CT (1) on per-lesion analysis (p= 0.001 Reader 1, p= 0.003 Reader 2, Fisher’s exact
test). However, on per-patient analysis compared to confirmed lesions on CELUS (20), no
difference was found (p= 0.429, Fisher’s exact test) between the lesions found on DWMR
(20) and the lesions found on CT (14 of 15).
Follow-up scans
The median time from surgery until the last follow-up scan was 25 months (range 2–48)
and 23 (range 1–46) in Groups-1 and -2, respectively. The type of control scan is shown in
Table 5.
In Group-1, follow-up scan compared to preoperative CT and CELUS revealed a
patient with additional synchronous liver metastases found two months after surgery.
Furthermore, one 38 mmmetachronous liver metastasis was found after 21 months in
another patient in Group-1.
Two patients in Group-2 were found with metachronous metastases on follow-up
scans. One patient with multiple metachronous liver lesions (5, 5, 18, 22 mm) was found
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after 15 months and one patient with one metachronous metastasis (30 mm) after 14
months. One patient did not undergo control scans due to severe co-morbidity.
DISCUSSION
The primary finding of this study was a per-patient sensitivity/specificity of 50/100% for
CT. For DWMR, the per-patient sensitivity/specificity was 100/94% and 100/100% for
Reader 1 and 2, respectively. The per-lesion sensitivity of CT and DWMR were
17% and 89%, respectively. Furthermore, one patient had non-resectable metastases after
DWMR, despite being diagnosed with resectable metastases after CT. Another patient was
diagnosed with multiple liver metastases during CELUS, despite a negative CT-scan.
The results of our study are in line with recent large meta-analyses which recom-
mended MRI for diagnosis of colorectal liver metastases (Floriani et al., 2010; Niekel,
Bipat & Stoker, 2010). In the latest meta-analysis comparing the modalities of CT, MRI
and FDG-PET, a pooled per-patient sensitivity and specificity of 75% and 96% for CT
compared to 81% and 97% for MRI, and 94% and 99% for FDG-PET were found. The
per-lesion sensitivity was 83% for CT, 86% for MRI and 86% for FDG-PET (Floriani
et al., 2010). However, both in the per-patient and per-lesion analyses of the diagnostic
modalities of MRI vs CT, the odds ratio [OR] (95% confidence interval) were in favor of
MR with an OR of 0.69 (0.47–0.99) and 0.66 (0.55–0.80), respectively. Furthermore, using
liver specific contrast agents in the per-lesions analysis, the difference was even more
pronounced (Floriani et al., 2010). To our knowledge no studies have been published
comparing CT and DWMR of the liver for diagnosis of liver metastases for colorectal can-
cer, but several trials have shown higher sensitivities of DWMR compared to conventional
MR imaging or MR with liver specific contrast (Parikh et al., 2008; Nasu et al., 2006).
The importance of preoperative evaluation of the liver cannot be overstated since
surgical treatment has been shown to have the best long-term survival rates. One study
found disease free survival at 5 and 10 years of 27% and 22%, respectively, with an
overall survival at 5 and 10 years being 47% and 28%, respectively (Wei et al., 2006).
Furthermore, there are other treatments, including RFA and perioperative chemotherapy
combined with surgery, which have a 4-year overall survival of 20–49% (Lee et al.,
2008; Park et al., 2008) and a 5-year overall survival of 51% (Nordlinger et al., 2013),
respectively. This is to be compared with patients with colorectal cancers having a 5-year
overall survival of 3.3% for untreated synchronous liver metastases (Manfredi et al., 2006)
or a mean survival of 8.5 months (Gorog, Toth & Weltner, 1997). However, common for
all treatment strategies and prognoses is that it solely relies on accurate staging, especially
for diagnosis of liver metastases.
The results of this trial also show that the sensitivity of contrast enhanced ultrasound
performed during surgery, as shown in several other studies (Shah et al., 2010; Zacherl et
al., 2002), was high and will find new liver metastases compared to preoperative staging.
Two trials reported at least one additional malignant lesion found on intraoperative
ultrasound in 12–33% of cases where pre-contrast CT followed by post-contrast CT scans
were used (Shah et al., 2010; Zacherl et al., 2002). However, an even more important
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finding of the studies, also underlined in this study, was that liver metastases could and
should be diagnosed prior to surgery as they may alter the treatment strategy. In the two
studies, change of surgical strategy was seen in 14–23% of the cases due to intraoperative
ultrasound findings (Shah et al., 2010; Zacherl et al., 2002). In this study, 3/15 (20%)
patients were inadequately diagnosed preoperatively with CT. One patient was found
inoperable after DWMR and thus underwent new adjuvant therapy before liver resection,
one patient had additional RFA and in the last case the patient underwent postoperative
chemotherapy as the lesions were not detected preoperatively. In worst case scenarios
inadequate preoperative assessment of the liver may result in futile laparotomies. This
has been described in up to 11% of patients with R0 colorectal cancer resections and
liver metastases who had a preoperative evaluation with CT (Ruers et al., 2009). The fact,
that CT of the liver may not be an adequate preoperative evaluation was demonstrated
in the same study, which also found a 60% potential reduction in futile laparotomies by
adding FDG-PET to CT-scan in the preoperative evaluation (Ruers et al., 2009). Besides
a futile laparotomy, more serious consequences arise from inadequate preoperative
staging as patients undergoing surgery with undetected liver metastases may progress
from having resectable metastases to non-resectable metastases. One obvious cause
of progression is the prevention or the delay in chemotherapy due to postoperative
complications. Complications may occur after any operation and especially in rectal
resections, which has been shown to have anastomotic insufficiency in up to 13%
(DCCG). Another hypothetical cause of progression in the liver metastases may be
the surgical stress following laparotomy. The degree of surgical stress is proportional
to the postoperative immunological decrease in the body (Baigrie et al., 1992). These
immunological changes lead to impaired immune function which may lead to increased
postoperative complications and increased morbidity (Baigrie et al., 1992; Ohzato et
al., 1992; Hensler et al., 1998). Furthermore, it has been shown, that a decrease in cell
mediated immune function by cytotoxic T-lymphocytes and NK-cells contribute to an
increased susceptibility to the growth of metastases in oncological patients having rectal
cancer (Koda et al., 2003; Kondo et al., 2003).
The weakness of the study is that only 57 patients were included in a period of three
years. Despite all efforts of recruiting patients consecutively, logistic problems resulted
in a low accrual rate. This may be a potential bias, but our patients were prospectively
and blinded randomized to minimize bias. Another weakness of the study was the fact,
that only 33 out of the 57 patients had CELUS and that assessment of potential missed
liver metastases were dependent on postoperative follow-up with a CT-scan. The results
may therefore be an overestimation of the sensitivity. The different modality used for the
postoperative control is another weakness which may yet again lead to an overestimation
of sensitivity and specificity. Furthermore, the fact that the radiologist who evaluated
the CT images was the one who was on duty, may have caused a bias in the outcome,
especially since the readers of DWMR and CELUS were dedicated and experienced
readers.
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CONCLUSIONS
Our study found DWMR to be feasible as a preoperative evaluation of liver metastases.
Furthermore, our study has shown potential disadvantages as a result of the current
standard preoperative evaluation by CT-scan. We recommend that patients with rectal
cancer, who are scheduled for MR of the rectum, should have a DWMR of the liver
performed at the same time.
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